Quote this publication Share Print

LOJUXTA

-
Opinions on drugs - Posted on May 30 2014

Reason for request

Inclusion

-


Actual benefit

Important

The actual benefit provided by LOJUXTA in combination with other lipid lowering medicines is substantial in adult patients with homozygous familial hypercholesterolaemia (HoFH) uncontrolled by these lipid-lowering treatments used at maximum doses, whether or not combined with apheresis.


Improvement in actual benefit

IV (mineur)

The addition of LOJUXTA to an optimal lipid-lowering therapy, used at maximum doses, whether or not combined with apheres is, in adult patients with uncontrolled homozygous familial hypercholesterolaemia (HoFH), provides a minor improvement in actual benefit (IABIV).